[go: up one dir, main page]

KR900700153A - 생리학적 활성물질 투여를 위한 폐색체 - Google Patents

생리학적 활성물질 투여를 위한 폐색체

Info

Publication number
KR900700153A
KR900700153A KR1019890701941A KR890701941A KR900700153A KR 900700153 A KR900700153 A KR 900700153A KR 1019890701941 A KR1019890701941 A KR 1019890701941A KR 890701941 A KR890701941 A KR 890701941A KR 900700153 A KR900700153 A KR 900700153A
Authority
KR
South Korea
Prior art keywords
reservoir
obturator
active substance
physiologically active
membrane
Prior art date
Application number
KR1019890701941A
Other languages
English (en)
Other versions
KR970009723B1 (ko
Inventor
존 마크 터커
마크 러퍼트 터커
Original Assignee
터커. 존 마크
마크 러퍼트 터커
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 터커. 존 마크, 마크 러퍼트 터커 filed Critical 터커. 존 마크
Publication of KR900700153A publication Critical patent/KR900700153A/ko
Application granted granted Critical
Publication of KR970009723B1 publication Critical patent/KR970009723B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

내용 없음

Description

생리학적 활설물질 투여를 위한 폐색체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예1의 반창고의 약횡단면도이다. 제2도 내지 7도는 3분을 주기로한 시간 200에 대한 방출 그래프이다.

Claims (16)

  1. 생리학적 활성 물질을 피부를 통해 투여하기 위한 폐색체에 잇어서, 상기 폐색체는 액체 형태의 생리학적 활성물질을 포함하는 저장소, 생리학적 활성 물질이 통과할수 있고 활성물질과 가까이 있는 미소다공질 막으로 구성된 저장소 벽, 및 저장소내의 점성의 유동겔에 의해 실제로 고정된 액체 내용물로 구성하되 a)상기 막(3)은 소수성이고, 상기 저장소는 친수성 습윤제를 포함하거나, b)상기 막(3)은 친수성이고 상기 저장소 내용물은 소수성인 생리학적 활성 물질을 피부를 통해 투여하기 위한 폐색체.
  2. 제1항에 있어서, 막(3)이 접착제(2)로 코팅된것을 특징으로 하는 폐색체.
  3. 제2항에 있어서, 접착제는 실리콘에 기초를 둔 접착제임을 특징으로 하는 폐색체.
  4. 상기 청구항중 어느 한 항에 있어서, 막(3)이 소수성이고 상기 저장소가 친수성 습윤제를 포함하는 것을 특징으로 하는 폐색체.
  5. 제4항에 있어서, 저장소 내용물은 점성도 저절제나 계면활성제 역활도 하는 가소제와 함께 무롤 구성되는 것을 특징으로 하는 폐색체.
  6. 제5항에 있어서, 계면 활성제는 메틸 셀룰로오즈로 구성되는 것을 특징으로 하는 폐색체.
  7. 제6항에 있어서, 메틸 셀룰로오즈의 양이 저장소 내용물에 관하여 무게당 약 5% 내지 6%인 것을 특징으로 하는 폐색체.
  8. 상기 청구항 중 어느 한 항에 있어서, 생리학적 활성물질이 니코틴인 것을 특징으로 하는 폐색체.
  9. 제8항에 있어서, 니코틴의 양이 저장소의 전체 액체 내용물의 무게당 2% 내지 10%인 것을 특징으로 하는 폐색체.
  10. 상기 청구항 중 어느 한 항에 있어서, 저장소 내용물이 차나무 기름을 포함하는 것을 특징으로 하는 폐색체.
  11. 제10항에 잇어서, 차나무 기름의 양이 저장소의 액체 내용물의 무게당 0.05%내지 2%인 것을 특징으로 하는 폐색체.
  12. 제1항 내지 7항 중 어느 한 항에 있어서, 생리학적 활성 물질이 파라세타몰, 에페드란, 펜타닐, 티몰올, 클로니딘, 히오스친, 에스트라디올, 프로게스테론, 살부타몰, 또는 테스토스테론인 것을 특징으로 하는 폐색체.
  13. 상기 청구항 중 어느 한 항에 있어서, 저장소가 금속 또는 플라스틱 엷은 판으로 된 불침투성 뒷받침(4)로 구성되는 것을 특징으로 하는 폐색체.
  14. 상기 청구항 중 어느 한 항에 있어서, 상기 생리학적 활성 물질이 저장소 내용물의 무게당 25%이상을 차지하지 않기 위하여 적어도 하나의 희석제와 함께 존재하는 것을 특징으로 하는 폐색체.
  15. 상기 청구항 중 어느 한 항에 있어서, 상기 저장소의 벽이 미소다공질 막의 외부 표면과 가까이 있는 침투성 막으로 구성되어 있고, 상시 침투성 막이 상기 미소다공질 막(3)의 습윤력과 같거나 다른 습윤력을 가지는 것을 특징으로 하는 폐색체.
  16. 폐색체가 액체 형태의 활성 물질을 포함하는 저장소, 활성 물질이 침투할수 있는 저장소 벽(3) 및, 차나무 기름이나 그의 주요성분을 부가적으로 포함하는 저장소로 구성된 것을 특징으로 하는 생리학적 활성 물질을 피부로 통해 투여하기 위한 폐색체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890701941A 1988-02-23 1989-02-23 생리학적 활성물질의 경피성 투여용 폐색체 KR970009723B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8804164 1988-02-23
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound
GB?88-04164? 1988-02-23
PCT/GB1989/000185 WO1989007959A1 (en) 1988-02-23 1989-02-23 Occlusive body for administering a physiologically active substance

Publications (2)

Publication Number Publication Date
KR900700153A true KR900700153A (ko) 1990-08-11
KR970009723B1 KR970009723B1 (ko) 1997-06-17

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890701941A KR970009723B1 (ko) 1988-02-23 1989-02-23 생리학적 활성물질의 경피성 투여용 폐색체

Country Status (11)

Country Link
US (1) US5254346A (ko)
EP (2) EP0508979B1 (ko)
JP (1) JP2716231B2 (ko)
KR (1) KR970009723B1 (ko)
AU (1) AU618085B2 (ko)
DE (1) DE68915291T2 (ko)
ES (1) ES2052071T3 (ko)
GB (1) GB8804164D0 (ko)
IN (1) IN172748B (ko)
WO (1) WO1989007959A1 (ko)
ZA (1) ZA891403B (ko)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
DE69108136T2 (de) * 1990-08-03 1995-11-02 Terumo Corp Wundabdeckmaterial.
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE9219105U1 (de) * 1992-10-31 1998-03-05 Klocke Verpackungs-Service GmbH, 76356 Weingarten Behälter zur Aufnahme von aromatischen Substanzen
JPH08503465A (ja) * 1992-11-09 1996-04-16 ファーメトリックス コーポレイション ケトロラックの経皮デリバリー
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
WO1995024172A1 (en) * 1994-03-07 1995-09-14 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
WO1999061007A1 (de) * 1998-05-22 1999-12-02 Novosis Pharma Ag Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
RU2276998C2 (ru) 2001-05-01 2006-05-27 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Гидрогелевые композиции
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
AU2002316053A1 (en) 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2492654A1 (en) * 2002-07-16 2004-01-22 University Of South Florida Human immunosuppressive protein
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス,インコーポレーテッド ノルケタミンおよびケタミン/ノルケタミンプロドラッグの鎮痛的使用
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
WO2004093788A2 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
CA2530996C (en) 2003-07-03 2013-05-07 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
WO2005013996A2 (en) 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
EP1663168B1 (en) * 2003-09-08 2009-02-11 McNeil AB Nicotine formulations and use thereof
EP1713450B1 (en) 2004-01-30 2021-10-06 Corium, Inc. Rapidly dissolving film for delivery of an active agent
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
AU2005238034A1 (en) * 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
MX2007001512A (es) 2004-08-05 2007-04-20 Corium Int Inc Composicion adhesiva.
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
ATE551995T1 (de) 2004-10-21 2012-04-15 Durect Corp Transdermale abgabesysteme
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP1965776A1 (en) * 2005-12-08 2008-09-10 Fertin Pharma Low flexural strength transdermal tobacco alkaloid patch
EP1965777A1 (en) * 2005-12-08 2008-09-10 Fertin Pharma Transdermal tobacco alkaloid patch
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US9109204B2 (en) * 2006-02-28 2015-08-18 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
NZ574361A (en) 2006-07-21 2012-02-24 Biodelivery Sciences Int Inc Transmucosal delivery devices with enhanced uptake containing buprenorphine
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Wnt信号伝達に関係した分泌タンパク質
DE602007012363D1 (de) 2006-10-19 2011-03-17 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen
ES2380551T3 (es) 2006-11-21 2012-05-16 Rigel Pharmaceuticals, Inc. Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
AU2007353989A1 (en) * 2007-05-31 2008-12-04 Fertin Pharma A/S Transdermal tobacco alkaloid reservoir patch
WO2009027850A2 (en) * 2007-06-06 2009-03-05 Multi-Tech Specialty Chemicals Co., Ltd. Process for the preparation of xanthophyll crystals
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
CN103508936A (zh) 2008-08-22 2014-01-15 赛诺菲-安万特 用于制备吲哚苄胺化合物的中间体
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
US8324200B2 (en) 2009-01-23 2012-12-04 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
BR112012000254A2 (pt) 2009-07-08 2016-02-16 Dermira Canada Inc análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
US20110034415A1 (en) * 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
WO2011022371A2 (en) * 2009-08-17 2011-02-24 Silipos Inc. Gel product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
CA2785439A1 (en) 2009-12-23 2011-06-30 Sanofi [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
PL2516418T3 (pl) 2009-12-23 2014-10-31 Sanofi Sa Proleki [4-[4-(5-aminometylo-2-fluoro-fenylo)-piperydyn-1-ylo]-(1H-pirolo-pirydynylo)-metanonów oraz ich synteza
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20110288103A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives
WO2011133600A1 (en) 2010-04-20 2011-10-27 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine sulfonamide derivatives
KR101379370B1 (ko) 2010-04-24 2014-03-28 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
US20120208855A1 (en) 2010-07-12 2012-08-16 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
PT2598500T (pt) 2010-07-28 2021-07-22 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
EP2632903A4 (en) 2010-10-28 2014-11-26 Viamet Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
SI2635299T1 (sl) 2010-11-02 2020-02-28 The Trustees Of Columbia University In The City Of New York Postopki za zdravljenje motenj izgube las
EP2638021B1 (en) 2010-11-13 2018-09-26 Innocrin Pharmaceuticals, Inc. 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer
EP2651905B1 (en) 2010-12-13 2017-07-19 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2654500B1 (en) 2010-12-20 2017-07-19 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
EP2678297A2 (en) 2011-02-25 2014-01-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chrysophaentin analogs that inhibit ftsz protein
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
EP3398944A1 (en) 2011-06-19 2018-11-07 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
AU2012273161B9 (en) 2011-06-19 2017-07-06 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
IN2014DN00286A (ko) 2011-06-23 2015-06-05 Viamet Pharmaceuticals Inc
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
EA033256B1 (ru) 2011-08-18 2019-09-30 Байоделивери Сайенсиз Интернэшнл, Инк. Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина
BR112014005104A2 (pt) 2011-09-02 2017-07-04 Salk Inst For Biological Studi inibidores camkii, ip3r, calcineurin, p38 e mk2/3 para tratar atar distúrbios metabólicos de obesidade
RS57248B1 (sr) 2011-12-11 2018-07-31 Viamet Pharmaceuticals Nc Inc Jedinjenja inhibitori metaloenzima
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
IN2014DN06792A (ko) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
AU2013235729B2 (en) 2012-03-23 2017-06-01 Baylor University Compositions and methods for inhibition of cathepsins
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2948150A1 (en) 2013-01-25 2015-12-02 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2015089310A1 (en) * 2013-12-11 2015-06-18 Atkinson Oscar Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
JP6625071B2 (ja) 2014-03-07 2019-12-25 ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 慢性疼痛用のナトリウムチャネルを標的とする非麻薬性crmp2ペプチド
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
SI3271347T1 (sl) 2015-03-19 2022-11-30 Mycovia Pharmaceuticals, Inc. Protiglivične spojine in postopki za izdelavo
ES2811136T3 (es) 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
US10308632B2 (en) 2015-09-18 2019-06-04 Vps-3, Inc. Antifungal compounds and processes for making
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
KR102240920B1 (ko) 2015-12-30 2021-04-16 브이피에스-3, 엘엘씨 금속 효소 억제 화합물
WO2017155906A1 (en) 2016-03-08 2017-09-14 Living Proof, Inc. Long lasting cosmetic compositions
ES2940911T3 (es) 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
EP3478091B1 (en) 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
US10370367B2 (en) 2016-10-26 2019-08-06 Rigel Pharmaceuticals, Inc. IRAK inhibitors and method for making and using
WO2018081294A1 (en) 2016-10-26 2018-05-03 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
DK3562487T3 (da) 2016-12-29 2024-01-02 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloenzyminhibitorforbindelser
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
EP3645525A1 (en) 2017-06-29 2020-05-06 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
US10987300B2 (en) 2017-09-13 2021-04-27 Living Proof, Inc. Long lasting cosmetic compositions
US10842729B2 (en) 2017-09-13 2020-11-24 Living Proof, Inc. Color protectant compositions
CN111356501A (zh) 2017-11-20 2020-06-30 生活实验公司 实现持久化妆品性能的属性
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
AU2019257739B2 (en) 2018-04-27 2025-01-09 Living Proof, Inc. Long lasting cosmetic compositions
SMT202300313T1 (it) 2018-05-03 2024-01-10 Rigel Pharmaceuticals Inc Composti inibitori di rip1 e metodi per realizzare e usare gli stessi
PE20210414A1 (es) 2018-05-03 2021-03-04 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
CA3147443A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
EP4013420B1 (en) 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
KR20220054626A (ko) 2019-08-30 2022-05-03 리겔 파마슈티칼스, 인크. 피라졸 화합물, 이의 제형, 및 화합물 및/또는 제형을 사용하는 방법
JOP20220056A1 (ar) 2019-09-06 2023-01-30 Rigel Pharmaceuticals Inc مركبات rip1 تثبيطية وطرق عملها واستخدامها
BR112022002581A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Inibidores heterocíclicos de rip1 quinase
US11578078B2 (en) 2019-11-07 2023-02-14 Rigel Pharmaceuticals, Inc. Heterocyclic RIP1 inhibitory compounds
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
CN119301121A (zh) 2022-03-23 2025-01-10 里格尔药品股份有限公司 作为irak抑制剂的嘧啶-2-基-吡唑化合物
US20230312568A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
AU1147476A (en) * 1975-03-19 1977-09-01 Procter & Gamble Controlled release article
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
ATE95430T1 (de) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
GB8512358D0 (en) * 1985-05-16 1985-06-19 Euro Celtique Sa Transdermal delivery system

Also Published As

Publication number Publication date
AU3289589A (en) 1989-09-22
DE68915291T2 (de) 1994-09-01
EP0508979A1 (en) 1992-10-21
JPH03503636A (ja) 1991-08-15
WO1989007959A1 (en) 1989-09-08
ZA891403B (en) 1989-11-29
EP0508979B1 (en) 1994-05-11
JP2716231B2 (ja) 1998-02-18
KR970009723B1 (ko) 1997-06-17
DE68915291D1 (de) 1994-06-16
EP0336543A1 (en) 1989-10-11
IN172748B (ko) 1993-11-20
US5254346A (en) 1993-10-19
ES2052071T3 (es) 1994-07-01
AU618085B2 (en) 1991-12-12
GB8804164D0 (en) 1988-03-23

Similar Documents

Publication Publication Date Title
KR900700153A (ko) 생리학적 활성물질 투여를 위한 폐색체
KR950007808A (ko) 약물투여용 의료용구
KR910016318A (ko) 이온 전기 도입법으로 딜리버리된 활성제의 피부내 농도를 증가시키는 방법 및 여기에 사용되는 조성물
US5071704A (en) Device for controlled release of vapors and scents
KR890701164A (ko) 피부침투성 치료 시스템
KR930703038A (ko) 증대된 약제 유량을 나타내는 아포화된 경피적 약제 전달장치
KR900701274A (ko) 남용 가능성을 감소시킨 용량 제형
KR890011585A (ko) 경피식 피임약제제형
DE69925936D1 (de) Vorrichtung zur lokalen verabreichung einer arznei in einer körperhöhle
KR880012216A (ko) 활성성분 배합물용 경피성 치료계
IE882898L (en) Solubility modulated drug delivery device
EP0922453A3 (en) Percutaneous absorption type preparation containing tulobuterol
DE69121881D1 (de) Hautelektrodenaufbau und dazugehöriges gerät zur transdermalen verabreichung von heilmitteln
KR900005969A (ko) 게스토덴을 함유하는 경피 투여용 제제
KR910007548A (ko) 활성성분 플래스터, 그의 제조방법 및 용도
DK0674913T3 (da) Ikke-okklusivt klæbende plaster til påföring af medicament i huden
JPS6485912A (en) User-activating transdermal treatment system
KR850700218A (ko) 약학 조성물
NO20023135L (no) <gamma>-IFN v¶skedråpeaerosol og fremgangsmåte for fremstilling av denne
SE8300577D0 (sv) Overdrag som tillforsekrar reglerad avgivning av akriva bestandsdelar fran biologiskt aktiva blandningar, i synnerhet farmaceutiska beredningar, jemte sett att framstella biologiskt aktiva blandningar med reglerad ....
CA2010225A1 (en) Therapeutic System for the Retarded and Controlled Transdermal or Transmucous Administration of Active Substances (1)
JPS56100716A (en) Drug administration member
KR100260323B1 (ko) 약액을구비한일회용밴드
US5558664A (en) Device for the dermal absorption of medicinal solutes
ATE205406T1 (de) Hauthaftende pharmazeutische zubereitung, insbesondere tts zur abgabe von 17-beta-estradiol an den menschlichen organismus

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19891023

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940221

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19891023

Comment text: Patent Application

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970522

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970912

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19971009

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19971009

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000617

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20010702

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030408

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20031021

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20041001

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060210

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20070406

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20070406

Start annual number: 10

End annual number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee